参考文献/References:
[1] Moreau C, Meguig S, Corvol JC, et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease[J]. Brain, 2015, 138 (Pt 5):1271-1283. DOI:10.1093/brain/awv063.
[2] Lin JJ, Yueh KC, Chang DC, et al. The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson’s disease for male, but not to female patients[J]. J Neurol Sci, 2003, 209 (1/2):87-92.
[3] 刘丰韬, 王坚. 遗传性帕金森病患者的脑功能显像[J]. 内科理论与实践, 2010, 5 (5):438-441. DOI:10.16138/j.1673-6087. 2010. 05.007. Liu FT, Wang J. Functional neuroimging in patients with inherited Parkinsonism[J]. J Intern Med Concepts Pract, 2010, 5 (5):438-441.
[4] Ma Y, Dhawan V, Mentis M, et al. Parametric mapping of[18F]FPCIT binding in early stage Parkinson’s disease:a PET study[J]. Synapse, 2002, 45 (2):125-133. DOI:10.1002/syn.10090.
[5] Liu SY, Wu JJ, Zhao J, et al. Onset-related subtypes of Parkinson’s disease differ in the patterns of striatal dopaminergic dysfunction:A positron emission tomography study[J]. Parkinsonism Relat Disord, 2015, 21 (12):1448-1453. DOI:10.1016/j.parkreldis.2015.10.017.
[6] Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease[J]. Mov Disord, 2015, 30 (12):1591-1601. DOI:10.1002/mds.26424.
[7] Guo JF, Wang L, He D, et al. Clinical features and[11C]-CFT PET analysis of PARK2, PARK6, PARK7-linked autosomal recessive early onset Parkinsonism[J]. Neurol Sci, 2011, 32 (1):35-40. DOI:10.1007/s10072-010-0360-z.
[8] Peng F, Sun YM, Chen C, et al. The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease:A five-year follow-up and literatures review[J]. J Neurol Sci, 2017, 373:23-26. DOI:10.1016/j.jns.2016.12.009.
[9] Shi CH, Mao CY, Zhang SY, et al. CHCHD2 gene mutations in familial and sporadic Parkinson’s disease[J/OL]. Neurobiol Aging, 2016, 38:217.e9-217.e13[2018-01-15]. http://www.ncbi.nlm.nih.gov/pubmed/26705026. DOI:10.1016/j.neurobiolaging.2015.10.040.
[10] 王元元, 吴平, 左传涛, 等. 不同重建算法对帕金森病相关脑功能网络的影响[J]. 中国医学计算机成像杂志, 2013, 19 (6):549-552. DOI:10.19627/j.cnki.cn31-1700/th.2013.06.018. Wang YY, Wu P, Zuo CT, et al. Influence of Different PET Reconstruction Algorithms on Parkinson’s Disease-related Pattern Expression[J]. Chin Comput Med Imag, 2013, 19 (6):549-552.
[11] 邱春, 左传涛, 张政伟, 等. 不同显像时间窗对11C-CFT PET/CT显像测多巴胺转运蛋白分布半定量值的影响[J]. 中华核医学与分子影像杂志, 2013, 33 (5):362-366. DOI:10.3760/cma.j.issn.2095-2848.2013.05.012. Qiu C, Zuo CT, Zhang ZW, et al. Influence of scanning time window on the binding potentials of dopamine transporter in the brain of healthy volunteers with 11C-CFT PET imaging[J]. Chin J Nucl Med Mol Imaging, 2013, 33 (5):362-366.
[12] Ramos CD, Erdi YE, Gonen M, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection[J]. Eur J Nucl Med, 2001, 28 (2):155-164.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[11]柴黎明,杨小丰,王爽,等.多巴胺转运体显像剂11C-CFT和18F-CFT及其临床应用进展[J].国际放射医学核医学杂志,2009,33(4):232.[doi:10.3760/cma.j.issn.1673-4114.2009.04.012]
CHAI Li-ming,YANG Xiao-feng,WANG Shuang,et al.Dopamine transporter imaging agent 11C-CFT and 18F-CFT and its clinical application development[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(5):232.[doi:10.3760/cma.j.issn.1673-4114.2009.04.012]
[12]于江,段玉清,毕常芬,等.多巴胺转运体PET显像剂11C-Altropane的研究进展[J].国际放射医学核医学杂志,2018,(1):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]
Yu Jiang,Duan Yuqing,Bi Changfen,et al.Progress of dopamine transporter PET imaging agent 11C-Altropane[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]